New study published in The Journal of Neuroscience highlights disease-modifying potential of Neurodon’s SERCA activators for Alzheimer’s disease
Alzheimer’s disease (AD) is a prevalent neurodegenerative disorder characterized by disrupted calcium signaling, synaptic dysfunction, and cognitive decline. Dysregulated calcium signaling is a key driver of AD pathogenesis, but previous efforts targeting calcium signaling proteins have been challenging due to potential side effects. Neurodon’s industry-leading positive allosteric modulators (PAMs) of the SERCA pump offer a […]
Neurodon CEO Dr. Russell Dahl to Present at the 20th FASEB Conference on Calcium and Cell Function
Neurodon Corp., a leader in the development of therapeutics targeting calcium homeostasis, is proud to announce that its CEO, Russell Dahl, Ph.D., will present at the 20th FASEB Conference on Calcium and Cell Function held in Winnipeg, Canada on July 6 – 10, 2025. Since 1987, this conference has been the eminent platform to present […]
Accomplished Biotech Executive Frederick Beddingfield III, M.D., Ph.D. Joins Neurodon’s Board
Accomplished Biotech Executive Frederick Beddingfield III, M.D., Ph.D. Joins Neurodon’s Board of Directors CROWN POINT, Ind., June 11, 2025 (GLOBE NEWSWIRE) — Neurodon Corp., a leader in the development of endoplasmic reticulum (ER) stress-targeted therapeutics for diabetes and neurodegeneration, welcomes Frederick Beddingfield, III, M.D., Ph.D., a 22-year veteran of the biopharma industry, to its Board […]
Neurodon Joins the Longevity Biotechnology Association (LBA)
There is a growing body of evidence that aberrant cellular calcium homeostasis, ER stress, and the UPR are correlated with aging and age-associated diseases such as neurodegeneration. Since Neurodon’s focus is on correcting this dysfunction, we envision leveraging our insight and small molecules to target aging both in a disease-focused and global manner. By partnering […]
U.S. Senator Todd Young Visits Neurodon’s Facilities
U.S. Senator Todd Young (R-IN) recently toured Neurodon’s laboratory and offices at its headquarters in Crown Point, Indiana. Senator Young and his team were interested to hear about Neurodon’s progress towards clinical translation of its novel small molecule therapeutics for Alzheimer’s disease, diabetes, and rare diseases. The Senator also took the opportunity to tour Neurodon’s […]
Neurodon Awarded Nearly $3 Million from NIH to Advance its Drug for Alzheimer’s Disease
This grant will be used for continued development and Investigational New Drug (IND)-enabling studies to support clinical translation of the company’s small molecule activators of the SERCA enzyme for Alzheimer’s disease. Neurodon’s novel molecules have demonstrated neuroprotective properties and the ability to improve learning and memory in several preclinical models of Alzheimer’s disease. To date, […]
JDRF and Neurodon Partner to Advance Small Molecules Targeting a Key Pathway in Type 1 Diabetes Progression
Research focused on understanding the role of beta cell dysfunction and death in T1D progression. Neurodon will work with Dr. Carmella Evans-Molina of the IU School of Medicine and Dr. Decio L. Eizirik of the ULB, both prominent physician scientists with research programs focused on understanding the role of beta cell dysfunction and death in […]
Curative Potential for Diabetes, Alzheimer’s, and Parkinson’s
A potential gamechanger for patients In addition to controlling blood glucose, the expert said data indicates Neurodon’s investigational diabetes drug restored beta cell health in several models of the disease, something no other drug on the market can do. Neurodon’s diabetes drug NDC-0009 has the potential to treat both Type 1 and Type 2 diabetes, […]
Neurodon Announces Initiation of IND-Enabling Studies for Diabetes
Neurodon aims to initiate clinical trials in the second half of 2022 “We are excited to achieve this milestone with the selection of a development candidate for our diabetes program. Our molecules have demonstrated compelling efficacy in both animal models and human pancreatic islets, and we are focused on developing first-in-class therapeutics to meaningfully impact […]
Neurodon Board Director Brunde Broady Releases New Book
About the book, Brunde Broady said, “Calcium ATPase is a critical component of good health. My goal is to provide the reader with research-based information on how to optimize their levels of this important enzyme and reduce their susceptibility to chronic diseases such as cancer, diabetes, obesity, cardiovascular disease, and Alzheimer’s.” Neurodon CEO, Dr. Russell […]